ALNYLAM PHARMACEUTICALS, INC. Payments for Capital Improvements
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Payments for Capital Improvements of $9.06 million for the 3-month period ending 2016-03-31, per its 10-Q filed 2017-05-05.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsForCapitalImprovements · last filed 2017-05-05
- ALNYLAM PHARMACEUTICALS, INC. payments for capital improvements for the quarter ending 2016-03-31 was $9.06M.
| Period end | Payments for Capital Improvements 3 month |
|---|---|
| 2016-03-31 | $9.06M 10-Q · filed 2017-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |